GM-1111
Solid Tumors (e.g., Colorectal, Lung, Renal, Breast, Endometrial)
Key Facts
About GlycoMira
GlycoMira is a private, clinical-stage biotech pioneering a first-in-class, innate immune-modulating therapeutic, GM-1111, derived from naturally occurring polysaccharides. The company has advanced GM-1111 into clinical trials with an FDA-accepted IND, supported by significant NIH grant funding and a strong intellectual property portfolio. Its dual strategy aims to enhance the efficacy of existing cancer therapies like radiation while mitigating debilitating side effects, positioning it to address substantial unmet needs in oncology.
View full company profileAbout GlycoMira
GlycoMira is a private, clinical-stage biotech pioneering a first-in-class, innate immune-modulating therapeutic, GM-1111, derived from naturally occurring polysaccharides. The company has advanced GM-1111 into clinical trials with an FDA-accepted IND, supported by significant NIH grant funding and a strong intellectual property portfolio. Its dual strategy aims to enhance the efficacy of existing cancer therapies like radiation while mitigating debilitating side effects, positioning it to address substantial unmet needs in oncology.
View full company profile